Centessa Pharmaceuticals PLC
NASDAQ:CNTA

Watchlist Manager
Centessa Pharmaceuticals PLC Logo
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Watchlist
Price: 22.2 USD -0.89% Market Closed
Market Cap: 3B USD

Operating Margin

-1 652.6%
Current
Improving
by 378.4%
vs 3-y average of -2 031%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 652.6%
=
Operating Income
$-247.9m
/
Revenue
$15m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-1 652.6%
=
Operating Income
$-247.9m
/
Revenue
$15m

Peer Comparison

Country Company Market Cap Operating
Margin
UK
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
3B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.7B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 99% of companies in United Kingdom
Percentile
1st
Based on 3 579 companies
1st percentile
-1 652.6%
Low
-195 650% — 0%
Typical Range
0% — 0.2%
High
0.2% — 4 630.7%
Distribution Statistics
United Kingdom
Min -195 650%
30th Percentile 0%
Median 0.1%
70th Percentile 0.2%
Max 4 630.7%

Centessa Pharmaceuticals PLC
Glance View

Market Cap
3B USD
Industry
Biotechnology

In the burgeoning landscape of biopharmaceutical innovation, Centessa Pharmaceuticals PLC stands out with a distinctive operating model that seeks to streamline the path from discovery to market. Centessa, founded in 2020, uniquely consolidates a range of biotech subsidiaries, each focused on distinct therapeutic areas. This structure enables them to maintain a sharp focus on scientific discovery while sharing corporate functions like operations, finance, and legal services to maximize efficiency. By integrating these companies under a single umbrella, Centessa hopes to mitigate the typical inefficiencies and bureaucratic delays that plague the path from pipeline to patient, driving forward their goal of developing transformative medicines. With an emphasis on nimblenes and productivity, Centessa monetizes its pipeline by advancing its most promising drug candidates through clinical development stages, subsequently seeking partnerships or acquisitions with larger pharmaceutical entities. The company's revenue stream hinges on the successful development and eventual commercialization or licensing of these pioneering therapies, often focusing on complex and challenging medical conditions. By nurturing a diverse portfolio of cutting-edge research programs — spanning areas like oncology, immunology, and rare diseases — Centessa strives to deliver breakthroughs that not only enhance patient lives but also provide substantial returns on investment through strategic collaborations and licensing deals within the pharmaceutical ecosystem.

CNTA Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-1 652.6%
=
Operating Income
$-247.9m
/
Revenue
$15m
What is Centessa Pharmaceuticals PLC's current Operating Margin?

The current Operating Margin for Centessa Pharmaceuticals PLC is -1 652.6%, which is above its 3-year median of -2 031%.

How has Operating Margin changed over time?

Over the last 2 years, Centessa Pharmaceuticals PLC’s Operating Margin has increased from -2 499.4% to -1 652.6%. During this period, it reached a low of -2 499.4% on Dec 31, 2023 and a high of -1 529.7% on Mar 31, 2025.

Back to Top